You are here: Industry Insights > Vraylar

News List

FDA Approves Expanded Use of Vraylar (cariprazine) in the Treatment of Bipolar Depression drugs
June 04, 2019
FDA Approves Expanded Use of Vraylar (cariprazine) in the Treatment of Bipolar Depression.
Allergan and Gedeon Richter Receive U.S. FDA Approval For Expanded Use of Vraylar (cariprazine) in the Treatment of Bipolar Depression drugs
May 29, 2019
Allergan and Gedeon Richter Receive U.S. FDA Approval For Expanded Use of Vraylar (cariprazine) in the Treatment of Bipolar Depression.
Allergan puts Vraylar on blockbuster track with new bipolar depression nod fiercepharma
May 29, 2019
Allergan, badly in need of good news, finally has some to share with investors.
FDA accepts Allergan’s Vraylar for review pharmatimes
September 29, 2018
The US Food and Drug Administration has accepted for review an application from Allergan to expand the scope of its antipsychotic Vraylar.
Allergan Receives FDA Approval for Use of VRAYLAR in Schizophrenia Treatment americanpharmaceuticacreview
November 14, 2017
Allergan announced the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine) for the maintenance treatment of adults with schizophrenia.
FDA approves Vraylar in the maintenance treatment of schizophrenia europeanpharmaceuticalreview
November 14, 2017
The FDA has approved the supplemental New Drug Application for Vraylarfor the maintenance treatment of adults with schizophrenia…
Allergan Receives Refusal to File Letter from FDA for Vraylar americanpharmaceuticacreview
September 26, 2017
Upon its preliminary review, FDA determined that the sNDA for treatment of negative symptoms was not sufficiently complete to permit a substantive review.
FDA Accepts Supplemental New Drug Application for Allergan’s VRAYLAR americanpharmaceuticalreview
March 09, 2017
Allergan has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company's supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine), seeking the addition of new clinical data evaluating VRAYLAR for the maintena